Evidence map›Paper›PMID 36388913›Full record

ArticleFrontiers in medicine2022

Tertiary lymphoid structures accompanied by fibrillary matrix morphology impact anti-tumor immunity in basal cell carcinomas.

Candice Byers, Melissa Gill, Nicholas R Kurtansky, Christi Alessi-Fox, Maggie Harman, Miguel Cordova, Salvador Gonzalez, Pascale Guitera, Veronica Rotemberg, Ashfaq Marghoob and 5 more

Open access · goldAbstract read
In one paragraph

Article in Frontiers in medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
0.8field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it, 10 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Review
  5. Article
  6. Article
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 6 institutions in 4 countries.

Candice ByersThe Institute for Experiential AI, Roux Institute, Northeastern University, Portland, ME, United States.
Melissa GillDepartment of Clinical Pathology and Cancer Diagnostics, Karolinska University Hospital, Stockholm, Sweden.
Nicholas R KurtanskyMemorial Sloan Kettering Cancer Center, New York, NY, United States.
Christi Alessi-FoxCaliber Imaging and Diagnostics, Rochester, NY, United States.
Maggie HarmanDepartment of Pathology, SUNY Downstate Health Sciences University, Brooklyn, NY, United States.
Miguel CordovaMemorial Sloan Kettering Cancer Center, New York, NY, United States.
Salvador GonzalezMemorial Sloan Kettering Cancer Center, New York, NY, United States.
Pascale GuiteraSydney Melanoma Diagnostic Center, Royal Alfred Prince Hospital, Camperdown, NSW, Australia.
Veronica RotembergMemorial Sloan Kettering Cancer Center, New York, NY, United States.
Ashfaq MarghoobMemorial Sloan Kettering Cancer Center, New York, NY, United States.
Chih-Shan Jason ChenMemorial Sloan Kettering Cancer Center, New York, NY, United States.
Jennifer DyDepartment of Electrical and Computer Engineering, Northeastern University, Boston, MA, United States.
Kivanc KoseMemorial Sloan Kettering Cancer Center, New York, NY, United States.
Milind RajadhyakshaMemorial Sloan Kettering Cancer Center, New York, NY, United States.
Aditi SahuMemorial Sloan Kettering Cancer Center, New York, NY, United States.
Memorial Sloan Kettering Cancer Center · USNortheastern University · USCaliber Imaging and Diagnostics (United States) · USKarolinska University Hospital · SEMelanoma Institute Australia · AUSUNY Downstate Health Sciences University · US

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Hongbiao Carl Lekaye · 1985 to 2026
$347.4M
Clinical and Translational Science AwardUL1TR001873 · NCATS · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI REILLY, MUREDACH P · 2016 to 2025
$99.0M
Disparities in COVID Disease Severity and Outcomes in New York CityUL1TR002384 · NCATS · WEILL MEDICAL COLL OF CORNELL UNIV · PI JULIANNE L IMPERATO-MCGINLEY · 2017 to 2026
$86.2M
Institutional Career Development CoreKL2TR002385 · NCATS · WEILL MEDICAL COLL OF CORNELL UNIV · PI YUAN-SHAN ZHU · 2017 to 2026
$13.3M
Simultaneous coaxial widefield imaging and reflectance confocal microscopy for improved diagnosis of skin cancers in vivoR01EB028752 · NIBIB · MONTANA STATE UNIVERSITY - BOZEMAN · PI CAMPS, OCTAVIA IRMA, DICKENSHEETS, DAVID LEE · 2020 to 2023
$2.4M
NCATS NIH HHS KL2 TR002385NCATS NIH HHS UL1 TR001873NCATS NIH HHS UL1 TR002384NCI NIH HHS P30 CA008748NIBIB NIH HHS R01 EB028752
6 · The paper itself

Abstract

Tertiary lymphoid structures (TLS) are specialized lymphoid formations that serve as local repertoire of T- and B-cells at sites of chronic inflammation, autoimmunity, and cancer. While presence of TLS has been associated with improved response to immune checkpoint blockade therapies and overall outcomes in several cancers, its prognostic value in basal cell carcinoma (BCC) has not been investigated. Herein, we determined the prognostic impact of TLS by relating its prevalence and maturation with outcome measures of anti-tumor immunity, namely tumor infiltrating lymphocytes (TILs) and tumor killing. In 30 distinct BCCs, we show the presence of TLS was significantly enriched in tumors harboring a nodular component and more mature primary TLS was associated with TIL counts. Moreover, assessment of the fibrillary matrix surrounding tumors showed discrete morphologies significantly associated with higher TIL counts, critically accounting for heterogeneity in TIL count distribution within TLS maturation stages. Specifically, increased length of fibers and lacunarity of the matrix with concomitant reduction in density and alignment of fibers were present surrounding tumors displaying high TIL counts. Given the interest in inducing TLS formation as a therapeutic intervention as well as its documented prognostic value, elucidating potential impediments to the ability of TLS in driving anti-tumor immunity within the tumor microenvironment warrants further investigation. These results begin to address and highlight the need to integrate stromal features which may present a hindrance to TLS formation and/or effective function as a mediator of immunotherapy response.

Indexed as

basal cell carcinoma (BCC)collagenextracellular matrix (ECM)fibrillary morphologymucintertiary lymphoid structures (TLS)tumor infiltrating lymphocyte (TIL)tumor microenvironment

Identifiers

PMID36388913
PMCPMC9647637
OpenAlexW4307630819

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.